← Back to patent-cliff list
Doxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust)
Tier C — Watch / tradeDoxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP2, DNA
Indications (approved)：Oesophageal cancer, 食道腺癌
Regional status
US
-
EU
Phase II
2010-02-24
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Doxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust)?
Approved indications include: Oesophageal cancer, 食道腺癌.
When does the Doxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust) patent expire?
No public expiry year is available for Doxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust) yet; this page updates once verified.
How do I get a quote for Doxorubicin in P-glycoprotein-targeting pluronics(Christie Hospital Nhs Foundation Trust) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21